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Abstract  
Background Systemic Lupus Erythematosus (SLE) is 
an autoimmune disease which involved many organs. 
One of its severe manifestations is lupus nephritis (LN). 
Treatment of LN consists of two phases, induction and 
maintenance. Inappropriate treatment approach could 
increase morbidity and mortality in LN patients. Renal 
flare is among many bad outcomes of LN that should be 
mitigated with an appropriate therapeutic approach. 
Various guidelines stated usage of mycophenolate 
mofetil (MMF) or azathioprine (AZA) as an appropriate 
immunosuppresant in the maintenance phase. However, 
it is not clear which agent acts best in preventing renal 
flare. This paper presents a case of 21 years old SLE 
female patient with history of renal flare 1 month prior to 
admission. This study aimed to give evidence-based 
recommendation to adjust this patient’s therapy in order 
to prevent future renal flare episode.  
Method Literature search was done on four online 
databases, namely PubMed, EBSCO, Cohrane Library, 
and ProQuest. Articles with randomized clinical trial 
(RCT), systematic review and meta-analysis study 
design were retrieved and selected based on inclusion 
and exclusion criterias. Critical appraisal was done using 
appraisal sheet provided by Oxford Centre of Evidence-
based Medicine. Articles were appraised based on its 
validity, importance, and applicability. 
Results There were 144 articles retrieved from literature 
searching. Further screening and full-text reading yields 
to 2 RCTs and 2 meta-analysis that were critically 
appraised. Both meta-analysis were satisfactory on their 
validity, while none of RCTs found were blinded studies. 
Both meta-analyses showed pooled risk ratio (RR) of 
0.70 (0.49 – 1.00) for renal flare outcome in the use of 
mycophenolate mofetil compared to azathioprine. 
Conclusion There are no significant differences 
between mycophenolate mofetil and azathioprine 
in prevention of renal flare. Based on applicability, 
azathioprine is more appropriate to be given in this 
patient, in accordance to her background. 
Keywords : Lupus Nephritis, Renal Flare, 
Mycophenolate Mofetil, Azathioprine, 
Systemic Lupus Erythematosus  
 
 
Introduction 
Systemic Lupus Erythematosus (SLE) is a complex 
autoimmune disorder which involved many 
 
 
organs. Lupus nephritis (LN) is one of its most severe 
complications. It is estimated that 60% of adult 
patients with SLE had this condition.1 Lupus nephritis 
has various severity grades. There was a classification 
system proposed by World Health Organization 
(WHO) which divides LN into six different classes 
based on histological and complex immune location 
properties, starting from mild mesangial proliferations 
to severe endothelial proliferations which may 
progress to sclerotic glomerular disease. A new 
classification is proposed by International Society of 
Nephrologist and Renal Pathology Society (ISN/RPS) 
to renew this classification by adding the categories of 
focal lesion, diffused, active, inactive, or chronic.2 
Renal involvement in SLE without appropriate 
treatment will lead to progressive deterioration of 
renal function, which in turns will increase morbidity 
and mortality. Inappropriate treatment may lead to 
undesirable outcomes such as End-Stage Renal 
Disease (ESRD) and even death.3 Therefore, main 
goal of LN treatment is to control the progression of 
disease itself in order to maintain normal renal 
function and prevent its deterioriation.  
Treatment of moderate/severe LN consists of 
induction phase continued by maintenance phase.4 
Generally, high dose corticosteroid and 
cyclophosphamides (CYC) are given during 
induction phase. As CYC may cause a number of 
severe adverse effects, including malignancy, 
therapeutic agents used during maintenance phase 
is alternated into low dose corticosteroid combined 
with immunosuppresant agent which is either 
mycophenolate mofetil (MMF) or azathioprine 
(AZA).5  
During maintenance, control of the symptoms 
with the lowest dosage possible that still prevent 
undesirable outcomes is preferable.  
Alongside ESRD or mortality, one of the bad 
outcomes of LN is renal relapse or renal flare. 
According to European League Against Rheumatism 
and European Renal Association-European Dialysis 
and Transplant Association (EULAR/ ERA-EDTA) in 
their recommendation6elicit expert opinions and reach 
consensus. Results Immunosuppressive treatment 
should be guided by renal biopsy, and aiming for 
complete renal response (proteinuria &lt;0.5 g/24 h 
with normal 
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or near-normal renal function, renal flare is defined as (i) 
nephritic flare, marked by increases serum creatinin by ≥30% 
(or decrease of GFR by ≥10%) with active urinary sediments 
and glomerular hematuria with ≥10 cells per high power field; 
and (ii) proteinuric flare, which is double in urine protein: 
creatinine ratio >100 mg/mmol following total remission or 
>200 mg/mmol after partial remission. Nephritic flare 
affected the kidney worse than proteinuric flare.6elicit expert 
opinions and reach consensus. Results Immunosuppressive 
treatment should be guided by renal biopsy, and aiming for 
complete renal response (proteinuria &lt;0.5 g/24 h with 
normal or near-normal renal function  
American College of Rheumatology (ACR) recommends 
AZA with target dose of 2 mg/kg/day or MMF with target dose 
of 2 g/day as immunosuppressant of choice in maintenance 
phase.5 However, none stated which one is the first choice among 
these two. Recommendation by Indonesian Rheumatology 
Association (IRA)4 also recommends either one of the two 
choices, with no preference of which one is better in preventing 
renal flare and other outcomes. Therefore, this article aimed to 
compare MMF and AZA for maintenance therapy of LN in 
preventing renal relapse. 
 
Case Ilustration 
Female, 21 years old, 40 kg, came to emergency department of 
Persahabatan Hospital with main complaint of ulcerations on 
both her feet for 7 days before admission. Patient started to feel 
fatigue also 7 days prior to admission, pustule-like lesions also 
started to appear in her abdomen, chest, and upper part of her both 
lower extremities. The lesions burst and excrete bloods and pus 1 
day before admission, so patients came to emergency department 
of Persahabatan Hospital. In the emergency unit, blood 
examination revealed her haemoglobin (Hb) level was 4.2 g/dL, 
so she got admitted after 500 mL packed red cells (PRC) 
transfusion. Patient has been diagnosed with SLE for 3 years, 
manifesting with frequent oral ulcers, photosensitivity, joint 
tenderness, and renal involvement. Previously, patient had 
methylprednisolone (MP) 1x8 mg and azathioprine 1x50 mg was 
added 1 year later. She had a recent history of hospital admission 
1 month ago due to massive edema all over her body and had 
previous regiment replaced with higher dose of MP 32 mg/day. 
Physical examination revealed dried skin, there were multiple 
dried ulcers on chest, abdomen, and lower limbs regions. 
Conjunctiva was pale, no oral ulcer. There is bilateral lower limb 
edema. Laboratory examination showed anemia, hypokalemia, 
and hypoalbuminemia. Initial laboratory analysis during 
admission revealed serum creatinine 1.3 mg/ dL and serum 
albumin 1.8 g/dL.  
The patient was then admitted with the following problems: 
SLE with haematology, mucocutaneous, and renal involvement, 
multiple ulcerations on lower limbs, abdomen, and chest 
considered to be vasculitis with secondary infection, 
hypokalemia, and hypoalbuminemia. Patient was planned to 
 
 
undergo electrolyte, ureum/creatinine, albumin, urinary, and 
microalbuminuria follow-up examination. Patient was treated 
with high protein diet, K-N2 intravenous fluid drainage 500 ml 
every 8 hours, meropenem 3 x 1 g IV, methylprednisolone 16-8-
8 mg, and potassium chloride 3x1200 mg. After 7 days of 
admission, she was planned to be discharged. Considering her 
history of renal relapse after maintenance therapy with 
azathioprine 1x50 mg and methylprednisolone 1x8 mg, we 
consider to alter her maintenance therapy in order to prevent 
future incident of renal flare. 
 
Method 
Based on the case, we arranged clinical question as follows: 
“In patients with lupus nephritis, is mycophonelate mofetil, 
compared to azathioprine, more effective in preventing renal 
flare?”  
To answer the question, literature search was done on four 
large electronic databases. Search on PubMed, EBSCO, 
Cochrane Library, and ProQuest was done with “lupus 
nephritis”, mycophenolate mofetil”, “azathioprine”, “renal 
flare”, and their synonyms. Literature search was done on 
November 15th 2017.  
During our literature search, we included Randomized 
Controlled Trials (RCTs), systematic review, and meta-analysis 
studies written in English or Indonesian. The articles included 
were published no earlier than January 1st, 2013. Articles with no 
available full-text were excluded. Our search within these 
limitations yielded 59 articles for title/abstract screening. 
Screening resulted in 12 articles, duplicate removal leaving 6 of 
them for full-text reading. Further reading yielded4 useful articles 
to be critically appraised using appraisal sheet from Center of 
Evidence-based Medicine, University of Oxford.7 Details of the 
search process is depicted in Figure  
1. We determined Level of Evidence of the articles based on 
criteria also published by Oxford Center of Evidence-based 
Medicine.8 Critical appraisal was done based on validity, 
importance, and applicability analysis. 
 
Figure 1. Literature Search Process  
 
 
 
 
 
 
 
 
 
 
 
 
 
Result 
Results of critical appraisal is summarized in Table 1 and 
Table 2. 
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Article 
 
Table 1. Critical appraisal of RCT studies 
 
Validity   Importance   Applicability  
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Kaballo et al9 + + + ? - 10.0% 9.8% 0.976 2.4% 0.2% 410 + + 2B 
Tamirou et al10 + + + + ? 42.3% 35.8% 0.847 15.3% 6.5% 16 + + 2B 
 
CER, control event rate; EER, experimental event rate; RR, relative risk; RRR, relative risk 
reduction; ARR, absolute risk reduction; NNT, number needed to treat. 
 
 
Table 2. Critical appraisal of Meta-analysis 
 
   Validity   Importance Applicability  
 
Fo
cu
se
dq
ue
st
io
n 
Se
ar
ch
st
ra
te
gy
 
st
u
d
y 
Q
ua
lit
yo
fs
tu
di
es
 
R
es
ul
ts
si
m
ila
rit
y 
 
S
im
ila
rit
yo
fs
tu
dy
an
dc
as
e 
V
al
ue
sa
nd
pr
ef
er
en
ce
so
fp
at
ie
nt
 
Le
ve
lo
fE
vi
de
nc
e
 
Article D
es
ig
na
nd
se
le
ct
io
nc
rit
er
ia
of
 th
e 
 
         
          
Feng et al11 + + + + + (assessed with + + 1A 
Maneiro et al12 + + + + + Forest Plot) + + 1A 
 
 
Apart of blinding, validities of both RCTs were satisfactory. 
Although we couldn’t find statements regarding characteristics of 
the subjects in the long-term follow up report of Tamirou et al10, 
a look in their original publication13 revealed similarities between 
the two groups. Tamirou et al did not explicitly state whether they 
utilized blinding, while Kaballo et al9 explained clearly that their 
study design was an open-label study. Both meta-analysis from 
Feng et al11 and Maneiro et al12 were valid with Level of Evidence 
of IA. Both Feng and Maneiro used Jadad score14 to assess the 
quality of RCTs included in their studies, and all RCTs included 
in the analysis scored 2−4 or 3−5, which considered as having 
good quality.  
While importance of both RCTs were determined by numbers 
shown in Table 1, importance analysis of meta-analysis studies 
by Feng et al and Maneiro et al were determined by observing 
forest plot shown in the study. There were four RCTs included in 
meta-analysis of both Feng et al and Maneiro et al, all of which 
were the same studies. Therefore, this study only analyzed forest 
plot shown by Feng 
 
 
et al in his study, which was identical with that of Maneiro et 
al, as shown in Figure 2.  
There is no significant heterogeneity from these four 
studies, as demonstrated with I2 = 0% (< 40%). An eyeball test 
on the forest plot supports this statement. Pooled risk ratio 
seems to favor MMF even though it does not reach statistical 
significance with relative risk (RR) 0.70 (0.49 – 1.00, 95% 
CI). 
 
Figure 2. Forest plot on renal flare outcome from Feng 
et al’s study. Left: favors MMF, right: favors AZA  
 
 
 
 
 
 
 
Favors MMF
 Favors AZA 
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Discussion 
Two RCTs critically appraised were both valid on their 
methods, even though they were not double-blinded studies. 
Even though this affect their scores on validity, we considered 
this to be tolerable, as the outcome measured in our article, 
renal flare, could be objectively measured, thus double-
blinding is not of utmost importance. Similarly, on both meta-
analysis we appraised, only 1 out of 4 RCTs included in the 
study was done with double-blinding. The other three were 
open-label studies.  
As shown in Table 1, usage of MMF in both RCTs 
resulting in RR < 1 which tends to favor its usage in order to 
prevent renal flare. However, statistical analysis of Kaballo et 
al resulted in p = 0.63, while Tamirou et al which had ‘time-
to-renal-flare’ as primary outcome of his study demonstrated 
hazard ratio of 1.22 (0.66 – 2.25 95% CI, p = 0.531). Both did 
not reach statistical significance. Our calculations shown in 
table 1 also demonstrate high value of number needed to treat 
(NNT) in both studies, which is 410 and 16 for the study of 
Kaballo et al and Tamirou et al, respectively. This supports 
that there are no significant differences, because to prevent 
renal flare to only one, hundreds must be involved in altering 
therapy.  
Study by Feng et al and Maneiro et al supports this 
statement. Pooled RR of 0.70 with 95% CI ranges from 0.49  
– 1.00 touches the line of no effect, which is 1.00. In addition, 
three out of four studies involved in the analysis showed RR with 
confidence interval that crosses this line of no effect.  
Based on that, we concluded that results of meta-analysis 
study also showed no significant differences for renal flare 
outcome in the use of MMF or AZA.  
This report has some limitations. First, definition of renal 
flare itself differs among studies. Tamirou et al defined renal 
flare as (1) proteinuric flare, which is development of 
nephrotic syndrome or three-fold increase of 24h proteinuria 
in 3 months period for those with low-grade baseline 
proteinuria (0.5−1 g); or (2) nephritic flare, a ≥33% increases 
in serum creatinine within a 1-month period directly attributed 
to lupus and confirmed. Meanwhile, Kaballo et al defined 
flare as (1) proteinuric flare: increase in 24h proteinuria of > 
2 g for patients with basal proteinuria of > 3 g, or doubled 24h 
proteinuria value for other patients; or (2) nephritic flare: 
increase of serum creatinine ≥50% with urinary nephritic 
sediments. Cut-off values in proteinuria or serum creatinine in 
these 2 studies were clearly different. RCTs involved in meta-
analysis also had these differences. One study by Houssiau et 
al13 had a similar definition with Tamirou et al’s study, while 
other studies had different cut-off values. One study even 
defined relapse only by clinical judgment, which includes 
need of increased steroid dose.15  
Second, methods of induction therapy were also different 
among studies. Kaballo et al gave pulse dose cyclophosphamide 
IV (500 mg/m2, 500 mg max) monthly for 6 months plus 3 
consecutive pulses of methylprednisolone IV (15 mg/kg/day, 
max 500 mg) as induction therapy, while Tamirou et al used pulse 
dose methylprednisolone IV 750 mg/day for 3 days plus  
6 times single-dose 500 mg cyclophosphamide given in the 
first 10 weeks. In studies analyzed by Feng et al, 2 studies 
 
 
gave another regiments for induction, one of them uses MMF 
in induction therapy. These differences could potentially cause 
bias in the results. However, one RCT analysed in study of 
Feng et al stated that MMF and cyclophosphamide as 
induction therapy showed consistent result regardless of the 
induction therapy, so potential bias caused by different 
induction therapy regiments could be reduced.  
Third, dosage of MMF or AZA for maintenance therapy 
also had its differences. Tamirou et al gave MMF with target 
dose of 2 g/day and AZA with target dose 2 mg/kg/day. 
Kaballo et al used similar dose for AZA, but MMF target dose 
were specified for 22 mg/kg/day with dose ranged from 1 to 3 
g/day. On the other hand, RCTs in the meta-analysis also used 
different doses. Two studies used MMF dose of 2 g/day, one 
targeted 1 g/day, while the other 0.5−3 g/day. As for AZA, two 
studies used similar target dose of 2 mg/kg/day, while the 
other two used different dose range of 1.5−2 mg/kg/day and 
1−3 mg/kg/day.12  
These differences in renal flare definition, induction 
regiments, and maintenance dose are all factors that may 
increase heterogeneity in this report, thus introduces potential 
risk of bias. However, regardless of these differences, we still 
found consistent results regarding renal flare outcome, which 
showed no significant differences between these two groups 
of maintenance therapy. Heterogeneity analysis on the meta-
analysis showed no significant heterogeneity seen on 
statistical perspectives with I2 < 40%.16  
From applicability perspective, MMF tends to have less 
adverse effects. Two outcomes that were analysed by Feng et al 
regarding adverse effect, which is leukopenia and amenorrhea, 
both favors MMF with significant reduced adverse event. 
However, MMF is not suitable to be consumed during pregnancy 
for its teratogenic effect.17 This has to be considered while treating 
woman with child-bearing age, such as this patient. Today, MMF 
is still more expensive, with prominent price different reaching to 
ten times more expensive than AZA.11,13 With no significant 
differences in preventing renal flare between MMF and AZA, we 
did not recommend change in maintenance therapy for this 
patient. One thing to be noted though, is the dosage of AZA 
received by this patient. Weighted 40 kg, this patient received 
AZA of only 50 mg/day, which is only 1.2 mg/kg/day. 
Meanwhile, most studies targeted AZA dose to 2 mg/kg/day. 
Therefore, we recommend dose of AZA to be adjusted in this 
patient. 
 
Conclusion 
Based on the results, we can conclude that there are no significant 
differences between MMF and AZA for maintenance therapy of 
LN in preventing renal flare. On applicability analysis, MMF had 
less adverse effects, but cost perspective and its teratogenic effect 
makes AZA a more appropriate choice for this patient. Therefore, 
we did not recommend alternation of maintenance therapy in this 
patient. 
 
Recommendation 
We recommend dose adjustment for AZA received by this 
patient to be increased to 2 mg/kg/day for a more optimum 
effect. Meta-analysis with less heterogeneity may be needed 
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to better demonstrate differences between AZA and MMF as 
maintenance therapy. 
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